Subscribe to RSS
DOI: 10.1055/s-0029-1246012
© Georg Thieme Verlag KG Stuttgart · New York
Outcome and Quality of Life Favour a Conservative Treatment of Patients with Primary Gastric Lymphoma
Therapieerfolg und Lebensqualität sprechen für eine konservative Therapie von Patienten mit primären MagenlymphomenPublication History
manuscript received: 2.9.2010
manuscript accepted: 28.12.2010
Publication Date:
07 April 2011 (online)
Zusammenfassung
Hintergrund: Sowohl chirurgische als auch konservative Therapiestrategien führen bei Patienten mit Magenlymphomen zu exzellenten Ergebnissen. Einen Vergleich von chirurgischer Resektion mit primärer Bestrahlung oder Chemotherapie in einem prospektiv randomisierten Ansatz gibt es bislang nicht. Ziel: Vergleich von chirurgischer Therapie mit Bestrahlung bei Patienten mit Marginalzonen-B-Zell-Lymphom (MZBZL) des MALT und von Chirurgie plus Chemotherapie mit alleiniger Chemotherapie bei Patienten mit diffusem großzelligen B-Zell-Lymphom (DGBZL) im Hinblick auf langfristigen Therapieerfolg und Lebensqualität. Methode: 49 Patienten (21 männlich und 28 weiblich; Alter 65 (35 – 75) Jahre) mit einem neu diagnostizierten MZBZL des MALT (n = 19) und DGBZL (n = 30) im Stadium I und II wurden eingeschlossen. Therapieerfolg und Lebensqualität, gemessen anhand des SF-36-Gesundheitsfragebogens und des Lebensqualitätsindexes (GLQI), wurden nach einem Beobachtungszeitraum von 74 (7 – 102) Monaten erhoben. Ergebnisse: Eine komplette Remission wurde bei Patienten mit MZBZL des MALT in 88 % nach chirurgischer Resektion und in 89 % nach Bestrahlung erreicht. Bei Patienten mit DGBZL führte eine Operation mit nachfolgender Chemotherapie in 93 % und eine alleinige Chemotherapie in 92 % zu einer kompletten Remission. Die Unterschiede zwischen den Therapiegruppen waren nicht signifikant. Die posttherapeutische Lebensqualität war generell hoch. Die Patienten mit konservativer Therapie wiesen gegenüber denjenigen, die sich einer Operation unterzogen hatten, eine signifikant bessere Lebensqualität auf. Schlussfolgerung: Der langfristige Therapieerfolg ist bei Patienten mit Magenlymphomen exzellent. Dies ist gilt für beide Lymphomentitäten und ist unabhängig davon, ob die Patienten chirurgisch oder konservativ behandelt werden. Vor dem Hintergrund der Lebensqualität sollte einer konservativen Therapiestrategie der Vorzug gegeben werden.
Abstract
Background: Both surgical and conservative treatment strategies offer an excellent outcome to patients with gastric lymphoma. No comparison of surgical resection with primary radiation or chemotherapy on a prospective randomised basis was available up to now. Aims: The aim of this study was to compare surgery with radiation and surgery plus chemotherapy with chemotherapy alone in patients with marginal zone B-cell lymphoma (MZBCL) of MALT and diffuse large B-cell lymphoma (DLBCL), respectively, with respect to long-term outcome and quality of life. Methods: 49 patients [21 male and 28 female; age 65 (35 – 75) years] with newly diagnosed MZBCL of MALT (n = 19) and DLBCL (n = 30) of stage I and II were recruited. Outcome was evaluated after a follow-up of 74 (7 – 102) months and quality of life was measured using the SF-36 health survey and the gastrointestinal life quality index (GLQI). Results: Complete remission rates in MZBCL of MALT were 88 % and 89 % in patients treated by surgery or radiotherapy, respectively. The corresponding rates for patients with DLBCL were 93 % following surgery plus chemotherapy and 92 % after chemotherapy alone, respectively. The results in the different treatment groups did not differ significantly. Posttherapeutic quality of life was generally high with a significant advantage for patients treated conservatively compared to those who underwent surgery. Conclusion: Long-term outcome of patients with gastric lymphoma is excellent irrespective of the lymphoma type and the treatment approach. Considering quality of life a conservative therapeutic strategy should be favoured.
Schlüsselwörter
Magenlymphomen - Marginalzonen-B-Zell-Lymphom des MALT - MALT-Lymphom - diffuses großzelliges B-Zell-Lymphom - chirurgische oder konservative Behandlung - Therapieerfolg
Key words
gastric lymphoma - marginal zone B-cell lymphoma of MALT - MALT lymphoma - diffuse large B-cell lymphoma - surgical and non-surgical treatment - outcome
References
- 1 Parlier Y, Najman A, Lecomte D et al. Results of a cooperative prospective study of treatment of primary digestive localisation of non-Hodgkin’s lymphoma. Gastroenterol Clin Biol. 1985; 9 922-928
- 2 Sheridan W P, Medley G, Brodie G N. Non-Hodgkin’s lymphoma of the stomach. A prospective pilot study of surgery plus chemotherapy in early and advanced disease. J Clin Oncol. 1985; 3 495-500
- 3 Steward W P, Harris M, Wagstaff J et al. A prospective study of the treatment of high-grade histology non-Hodgkin’s lymphoma involving the gastrointestinal tract. Eur J Clin Oncol. 1985; 21 1195-1200
- 4 Rackner V L, Thirlby R C, Ryan J A. Role of surgery in multimodality therapy for gastrointestinal lymphoma. Am J Surg. 1991; 161 570-575
- 5 Fung C Y, Grossbard M L, Linggood R M et al. Mucosa-associated lymphoid tissue lymphoma of the stomach: long term outcome after local treatment. Cancer. 1999; 85 9-17
- 6 Kodera Y, Yamamura Y, Nakamura S et al. The role of radical gastrectomy with systematic lymphadenactomy for the diagnosis and treatment of primary gastric lymphoma. Ann Surg. 1998; 227 454-450
- 7 Ruskone-Fourmestraux A, Aegerter P, Delmer A et al. Primary digestive tract lymphoma: a prospective multicentric study of 91 patients. Gastroenterology. 1993; 105 1662-1671
- 8 Fischbach W, Dragosics B, Koelve-Goebeler M E et al. Primary gastric B-cell Lymphoma: Results of a Prospective Multicenter Study. Gastroenterology. 2000; 119 1191-1202
- 9 Maor M H, Velasquez W S, Fuller L M et al. Stomach conservation in stages IE and IIE gastric non-Hodgkin’s lymphoma. J Clin Oncol. 1990; 8 255-271
- 10 Solidoro A, Payet C, Sanchez Lihon J et al. Gastric lymphomas: chemotherapy as a primary treatment. Semin Surg Oncol. 1990; 6 218-225
- 11 Haim N, Leviov M, Ben-Arieh Y et al. Intermediate and high-grade gastric non-Hodgkin’s lymphoma: a prospective study of non-surgical treatment with primary chemotherapy, with and without radiotherapy. Leuk Lymph. 1995; 17 321-326
- 12 Hammel P, Haioun C, Chaumette M T et al. Efficacy of single-agent chemotherapy in low-grade B-cell mucosa- associated lymphoid tissue lymphoma with prominent gastric expression. J Clin Oncol. 1995; 13 2524-2529
- 13 Schechter N R, Portlock C S, Yahalom J. Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol. 1998; 16 916-921
- 14 Tsang R W, Gospodarowicz M K, Pintilie M. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol. 2003; 21 4157-4164
- 15 Koch P, Probst A, Berdel W E et al. Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02 / 96). J Clin Oncol. 2005; 23 7050-7059
- 16 Swerdlow S H, ed WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008: 229-232
- 17 Eypasch E, Wood-Dauphinee S, Williams J I et al. Der Gastrointestinale Lebensqualitätsindex (GLQI). Ein klinimetrischer Index zur Befindlichkeitsmessung in der gastroenterologischen Chirurgie. Chirurg. 1993; 64 264-274
- 18 Fischbach W, Malfertheiner P, Hoffmann J C et al. S3-Leitlinie „Helicobacter pylori und gastroduo-denale Ulkuskrankheit” der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS) in Zusammenarbeit mit der Deutschen Gesellschaft für Hygiene und Mikrobiologie, Gesellschaft für Pädiatrische Gastroenterologie und Ernährung e. V. und der Deutschen Gesellschaft für Rheumatologie – AWMF-Register-Nr. 021 / 001. Z Gastroenterol. 2009; 47 68-102
- 19 Brands F, Monig S P, Raab M. Treatment and prognosis of gastric lymphoma. Eur J Surg. 1997; 163 803-813
- 20 Aviles A, Nambo M J, Neri N et al. The role of surgery in primary gastric lymphoma: results of a controlled clinical trial. Ann Surg. 2004; 240 44-50
- 21 Koch P, Probst A, Berdel W E et al. Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02 / 96). J Clin Oncol. 2005; 23 7050-7059
- 22 Cogliatti S B, Schmid U, Schumacher U et al. Primary B-cell gastric lymphoma: a clinicopathological study of 145 patients. Gastroenterology. 1991; 101 1159-1170
- 23 Zinzani P L, Frezza G, Bendandi M et al. Primary gastric lymphoma: a clinical and therapeutic evaluation of 82 patients. Leuk Lymphoma. 1995; 19 461-466
- 24 Vaillant J C, Ruskone-Fourmestraux A, Aegerter P et al. Management and long-term results of surgery for localized gastric lymphomas. Am J Surg. 2000; 179 216-222
- 25 Sano T. Treatment of primary gastric lymphoma: experience in the National Cancer Center Hospital, Tokyo [In Process Citation]. Recent Results Cancer Res. 2000; 156 104-107
- 26 Koch P, del Valle F, Berdel W E et al. Primary gastrointestinal non-Hodgkin’s lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma results of the prospective German Multicenter Study GIT NHL 01 / 92. J Clin Oncol. 2001; 19 3874-83
- 27 Kodera Y, Yamamura Y, Nakamura S et al. The role of radical gastrectomy with systematic lymphadenectomy for the diagnosis and treatment of primary gastric lymphoma. Ann Surg. 1998; 227 45-50
- 28 Kuo S H, Chen L T, Wu M S et al. Long-term follow-up of gastrectomized patients with mucosa-associated lymphoid tissue lymphoma : need for a revisit of surgical treatment. Ann Surg. 2008; 247 265-269
- 29 Wotherspoon A C, Doglioni C, Diss T C et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa- associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 1993; 342 575-577
- 30 Steinbach G, Ford R, Glober G et al. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann Intern Med. 1999; 131 88-95
- 31 Ruskone-Fourmestraux A, Lavergne A, Aegerter P H et al. Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment. Gut. 2001; 48 297-303
- 32 Bayerdorffer E, Neubauer A, Rudolph B et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet. 1995; 345 1591-1594
- 33 Montalban C, Santon A, Boixeda D et al. Treatment of low grade gastric mucosa-associated lymphoid tissue lymphoma in stage I with Helicobacter pylori eradication. Long-term results after sequential histologic and molecular follow-up. Haematologica. 2001; 86 609-617
- 34 Roggero E, Zucca E, Pinotti G et al. Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue. Ann Intern Med. 1995; 122 767-769
- 35 Neubauer A, Thiede C, Morgner A et al. Cure of Helicobacter pylori infection and duration of remission of low- grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst. 1997; 89 1350-1355
- 36 Nakamura S, Matsumoto T, Suekane H et al. Long-term clinical outcome of Helicobacter pylori eradication for gastric mucosa-associated lymphoid tissue lymphoma with a reference to second-line treatment. Cancer. 2005; 104 532-540
- 37 Fischbach W, Goebeler-Kolve M E, Dragosics B et al. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut. 2004; 53 34-37
- 38 Wundisch T, Thiede C, Morgner A et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol. 2005; 23 8018-8024
- 39 Burgers J M, Taal B G, Heerde van P et al. Treatment results of primary stage I and II non-Hodgkin’s lymphoma of the stomach. Radiother Oncol. 1988; 11 319-326
- 40 Kocher M, Muller R P, Ross D et al. Radiotherapy for treatment of localized gastrointestinal non-Hodgkin’s lymphoma. Radiother Oncol. 1997; 42 37-41
- 41 Schechter N R, Portlock C S, Yahalom J. Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol. 1998; 16 1916-1921
- 42 Thieblemont C, Dumontet C, Bouafia F et al. Outcome in relation to treatment modalities in 48 patients with localized gastric MALT lymphoma: a retrospective study of patients treated during 1976 – 2001. Leuk Lymphoma. 2003; 44 257-262
- 43 Tsang R W, Gospodarowicz M K, Pintilie M et al. Stage I and II MALT lymphoma: results of treatment with radiotherapy. Int J Radiat Oncol Biol Phys. 2001; 50 1258-1264
- 44 Vrieling C, Jong de D, Boot H et al. Long-term results of stomach-conserving therapy in gastric MALT lymphoma. Radiother Oncol. 2008; 87 405-411
- 45 Tomita N, Kodaira T, Tachibana H et al. Favorable outcomes of radiotherapy for early-stage mucosa-associated lymphoid tissue lymphoma. Radiother Oncol. 2009; 90 231-235
Prof. Dr. Wolfgang Fischbach
Medizinische Klinik II und Klinik für Palliativmedizin, Klinikum Aschaffenburg, Akademisches Lehrkrankenhaus der Universität Würzburg
Am Hasenkopf
63739 Aschaffenburg
Germany
Phone: ++ 49/60 21/32 30 10
Fax: ++ 49/60 21/32 30 31
Email: med2-aschaffenburg@t-online.de